Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Oil Fund (DBO) vs DexCom, Inc. (DXCM) Price & Performance

Invesco DB Oil FundTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

Invesco DB Oil Fund vs DexCom, Inc. — how do they compare? Invesco DB Oil Fund trades at $20.16, while DexCom, Inc. trades at $72.58 (market cap $28.60B). The key difference: Invesco DB Oil Fund is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.

DBODXCM
Sector
Commodities - EnergyHealth
52-Week High
$23.80$89.53
52-Week Low
$11.98$54.84
Market Cap
$28.60B
Enterprise Value
$27.57B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Oil Fund

DBO is trading at $19.59, up 8.47% with strong bullish momentum driven by escalating Middle East tensions that are boosting oil prices. Technical indicators show a bullish trend with support at $19 and resistance at $20, though RSI suggests potential overbought conditions. The stock benefits from geopolitical events that typically drive energy sector performance.

The outlook remains positive as oil price strength translates to potential revenue growth for US energy companies. Key risks include geopolitical volatility and potential supply disruptions. Analyst sentiment appears constructive given the favorable oil market dynamics, though fundamental metrics require verification from recent SEC filings.

DexCom, Inc.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco DB Oil Fund

DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.

Read more on DBO

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM